Johnson & Johnson Unveils Dual Booths Spanning Over 1,000 Square Meters at the Third China International Import Expo

Shanghai, October 29, 2020 /PRNewswire/ -- With one week to go until the opening of the Third China International Import Expo (CIIE), preparations for participation have entered their final sprint. As one of the largest exhibitors in the Medical Devices and Pharmaceuticals & Healthcare Zone at this year’s CIIE, a vice-chair unit of the Exhibitor Alliance in the previous two editions, and a deputy director unit of the Professional Committee for the Public Health and Epidemic Prevention Zone at the current expo, Johnson & Johnson will participate under the theme “Innovation-Driven Support for Healthy China.” The company will occupy a total exhibition area of over 1,000 square meters across dual booths, comprehensively showcasing its innovative development as a global leader in healthcare and highlighting its outstanding contributions to supporting China and the world in combating the epidemic and building robust public health systems. During the CIIE, Johnson & Johnson will also hold signing ceremonies and product launch events with various partners to deepen cooperation and share opportunities.

Innovation-Driven Development Supports Healthy China

This year, the total area of the Johnson & Johnson booth has expanded to twice its size from last year. Dominated by the highly recognizable “Johnson & Johnson Red” and white, the overall design is more open and bright, exuding a stronger sense of technology and futurism, fully embodying the key concept of “innovation.” The main Johnson & Johnson booth is divided into three thematic exhibition zones: “Review of Innovation Journey,” “Display of Innovative Products,” and “Collaborative Innovation for the Future.” It comprehensively showcases Johnson & Johnson’s significant milestones in serving patients and consumers and improving human health—ranging from its 35-year innovation journey in China, to innovative products and solutions across its Medical Devices, Pharmaceuticals, Consumer Health, and Vision Care business segments, and further to its active collaboration with various partners to build an open innovation ecosystem.

In the Innovation Journey Review Exhibit, Johnson & Johnson presents a narrative wall depicting the company’s innovation highlights since its entry into the Chinese market in 1985. Over 35 years of deep commitment to China, guided by the principles of its Credo, Johnson & Johnson has remained dedicated to addressing the health needs of Chinese patients and consumers. This journey spans from introducing innovative products, building advanced intelligent manufacturing capabilities, and upgrading its end-to-end global supply chain, to establishing a China-based innovation engine and cultivating an open innovation ecosystem—advancing together through collaborative innovation toward a healthier future for humanity. Johnson & Johnson remains firmly committed to supporting China’s high-quality development, fully backing the Healthy China initiative, and continuously promoting the long-term advancement of China’s healthcare industry and public health endeavors.

At the Innovative Products Exhibition Area, Johnson & Johnson’s MedTech, Pharmaceutical, Consumer Health, and Vision Care businesses will showcase innovative products, technologies, and solutions covering the entire human lifespan, including 7 global debuts, 12 Asian debuts, and 34 China debuts.

EmboTrap II Distal Occlusion Double-Layer Basket Thrombectomy Device

Zhaoke® (daratumumab injection), an innovative product for the treatment of multiple myeloma

Rogaine, Johnson & Johnson’s Professional Hair Regrowth Brand

Johnson & Johnson Vision’s Integrated Dry Eye Diagnosis and Treatment Solution: The Lipi Product Family

In the “Co-Innovating for the Future” exhibition zone, Johnson & Johnson will showcase its unique and cutting-edge innovation philosophy. On one hand, the company pursues both internal independent innovation and external innovation to better identify and implement innovative ideas, achieving continuous breakthroughs. On the other hand, leveraging Johnson & Johnson’s cross-business scientific expertise, market insights, and global influence, the company provides end-to-end support for innovation and R&D. In particular, by building an open innovation ecosystem and establishing initiatives such as the Johnson & Johnson Asia Pacific Innovation Center and the JLABS innovation incubator, it accelerates the R&D and growth of startups, making positive contributions to human health and well-being. Notably, a mini version of JLABS @ Shanghai—the largest JLABS incubator globally and the first in the Asia Pacific region—will also be featured at the booth, showcasing incubation achievements from relevant startups.

"Fully support public health and epidemic prevention and control work."

At the Public Health and Epidemic Prevention Zone, newly launched at this year’s China International Import Expo (CIIE), the Johnson & Johnson booth will highlight the company’s unwavering commitment to supporting public health and epidemic response efforts. Since the onset of the COVID-19 pandemic this year, Johnson & Johnson has fully supported anti-epidemic initiatives in China and worldwide by actively donating scarce medical protective supplies, medicines, products, and cash through global and local procurement channels, with total contributions exceeding RMB 30 million. Meanwhile, Johnson & Johnson has collaborated with global partners to accelerate vaccine research and development, enhance global manufacturing and supply capabilities, and promote public vaccine education through science popularization documentaries.

Johnson & Johnson has established a Global Public Health department dedicated to creating a healthier future for populations lacking adequate medical resources worldwide. Over the years, Johnson & Johnson has provided transformative innovative medical products and solutions across multiple public health domains, including infectious disease prevention and control, mental health improvement, and the promotion of individual wellness. The company actively advocates for public health collaboration and drives positive actions to reform public health models. For instance, Sirturo® (bedaquiline), introduced to China by Xi’an Janssen Pharmaceutical Ltd., a subsidiary of Johnson & Johnson, is the first new anti-tuberculosis drug approved in China in over 40 years. Prior to the approval of Sirturo®, patients with multidrug-resistant tuberculosis (MDR-TB) could only be treated with drugs developed before the 1960s. Furthermore, Johnson & Johnson collaborates with local organizations through various care initiatives targeting specific populations, ranging from medication donations and myopia screening to charitable surgeries and the dissemination of medical resources, thereby truly delivering innovative public health products and solutions to patients and communities.

Medical Innovation and Digital Transformation Leading the Future of Health

Currently, with the advancement of new technologies such as artificial intelligence and digitalization, frontier technologies are accelerating their integration with the healthcare sector. “Enhancing the capacity for scientific and technological innovation support” and the “new infrastructure” centered on 5G, industrial internet, and artificial intelligence have been incorporated into the Government Work Report. Against this backdrop, the emerging smart and digital transformation and development in the healthcare field will help better meet Chinese people’s demand for innovative medical products and services.

During the third China International Import Expo (CIIE), Johnson & Johnson will support the “Fourth Industrial Revolution and Smart Healthcare Forum,” jointly hosted by the Investment and Technology Promotion Office of the United Nations Industrial Development Organization (UNIDO) and the Guoshi Forum of China News Service. Themed “Healthcare Innovation and Digital Transformation Leading the Future of Health,” the forum will take place on the morning of November 7. Song Weiqun, Senior Vice President of Johnson & Johnson and Chairman of Johnson & Johnson China, and Asgar Rangoonwala, Member of the Johnson & Johnson China President Committee and President of Xian Janssen Pharmaceutical Ltd., will attend the event. They will join other distinguished guests and senior experts in the fields of healthcare innovation and digital public health, including relevant leaders from the Department of Planning, Development, and Informatization of the National Health Commission; Zhou Yanli, Member of the National Committee of the Chinese People’s Political Consultative Conference, Special Researcher of the Counselors’ Office of the State Council, and former Deputy Secretary of the Party Leadership Group and Vice Chairman of the China Insurance Regulatory Commission; Cai Jiangnan, Founder and Executive Director of the Shanghai Chuangqi Health Development Research Institute; Zeng Guang, Member of the High-Level Expert Group of the National Health Commission and former Chief Scientist of Epidemiology at the Chinese Center for Disease Control and Prevention; Lu Qingjun, Director of the National Telemedicine and Internet Medicine Center and Director of the Hospital Development Office at China-Japan Friendship Hospital; and Zhang Wenhong, Head of the Shanghai Expert Group for Clinical Treatment of COVID-19 and Director of the Department of Infectious Diseases at Huashan Hospital Affiliated to Fudan University. Together, they will engage in in-depth discussions on the opportunities and challenges associated with building smart healthcare systems and digital public health infrastructure, actively provide recommendations to promote industry development, and contribute to the early realization of the grand vision of “Healthy China.”

“As a long-standing friend of the China International Import Expo (CIIE), Johnson & Johnson places great importance on this vital platform for openness, innovation, and cooperation. We look forward to leveraging the CIIE to showcase our globally leading innovative products across all business segments to our partners, driving development through innovation and contributing to the Healthy China initiative,” said Song Weiqun, Global Senior Vice President and Chairman of Johnson & Johnson China. “In the new normal in the post-pandemic era, the continuously improving business environment in the Chinese market, the public’s demand for high-quality healthcare products and services, and the market’s expectations for innovative technologies will continue to inject strong momentum into the development of foreign enterprises, including Johnson & Johnson, in China. Johnson & Johnson will continue to strengthen China’s position as its top global growth engine, actively building it into a global hub for innovation and digital development. While continuously introducing innovative products into China, we will also promote innovations originating from China to the global market, working together to improve the health and well-being of people worldwide.”